2008
Clinically Tolerated Strategies for NMDA Receptor Antagonism
Vincent Chen H, Zhang D, Lipton S. Clinically Tolerated Strategies for NMDA Receptor Antagonism. The Receptors 2008, 327-361. DOI: 10.1007/978-1-59745-055-3_8.Peer-Reviewed Original ResearchExcessive NMDAR activityNMDAR activityClinical trialsGlutamate receptorsSide effectsNeurologic disordersNervous systemAcute hypoxic-ischemic brain injuryGeneralized inhibitionAlzheimer's diseaseSecond-generation memantine derivativesHypoxic-ischemic brain injuryPhase 3 clinical trialsExcessive NMDAR activationSevere neuropathic painExcitatory amino acidsGlutamate-mediated neurotoxicityGlutamate receptor subtypesChronic neurodegenerative diseasesSystemic side effectsMajor excitatory transmitterNormal functionNMDA receptor antagonismGreater neuroprotective propertiesCentral nervous system
2001
Potential and Current Use of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Diseases of Aging
Le D, Lipton S. Potential and Current Use of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Diseases of Aging. Drugs & Aging 2001, 18: 717-724. PMID: 11735619, DOI: 10.2165/00002512-200118100-00001.Peer-Reviewed Original ResearchConceptsReceptor antagonistN-methyl-D-aspartate receptor antagonistN-methyl-D-aspartate (NMDA) receptor complexSafe NMDA antagonistMultiple clinical trialsNMDA receptor antagonistChronic painClinical trialsNMDA antagonistsGlutamate receptorsParkinson's diseaseNeurological disordersNeurodegenerative diseasesDiseaseAdverse effectsAntagonistReceptor complexCurrent useDrugsAdequate levelPainMemantineDysfunctionNitroglycerinStroke
1998
A phase I/II trial of nimodipine for HIV-related neurologic complications
Navia B, Dafni U, Simpson D, Tucker T, Singer E, McArthur J, Yiannoutsos C, Zaborski L, Lipton S. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998, 51: 221-228. PMID: 9674806, DOI: 10.1212/wnl.51.1.221.Peer-Reviewed Original ResearchConceptsAIDS dementia complexVoltage-dependent calcium channel antagonistsPhase I/II trialSevere AIDS-dementia complexHigh-dose armPhase II studyFurther clinical trialsCalcium channel antagonistsNPZ-8Adjuvant treatmentAntiretroviral therapyII trialNeurologic complicationsNeuropsychological z scoresNeuronal injuryHIV infectionPeripheral neuropathyTreat analysisCSF levelsDementia complexImmune activationClinical trialsNeurologic disordersChannel antagonistsPossible efficacy
1997
Neuropathogenesis of acquired immunodeficiency syndrome dementia
Lipton S. Neuropathogenesis of acquired immunodeficiency syndrome dementia. Current Opinion In Neurology 1997, 10: 247-253. PMID: 9229134, DOI: 10.1097/00019052-199706000-00014.Peer-Reviewed Original ResearchConceptsImmunodeficiency syndrome (AIDS) dementiaImmunodeficiency syndrome (AIDS) patientsPotential new treatmentCentral nervous systemDevelopment of therapiesAntiretroviral therapyNeuronal injuryBrain macrophagesImmunodeficiency syndromeAntiretroviral drugsNeuronal deathHuman immunodeficiencySurrogate markerClinical trialsSyndrome patientsDirect infectionCerebrospinal fluidNervous systemPast year progressNew treatmentsViral productsTherapyDementiaOne-thirdFurther characterization